Scientists are discovering that one tiny peptide may help preserve the body’s cellular power plants—and protect the kidneys from damage.

When most people think about kidney disease, they think about blood pressure, diabetes, or aging.

Researchers, however, are increasingly looking somewhere much smaller.

Inside the mitochondria.

These microscopic structures are often called the powerhouses of the cell because they generate nearly all of the energy our cells need to survive. Nowhere is that energy more important than in the kidneys.

Every day, your kidneys filter approximately 180 liters of blood, continuously removing waste, balancing electrolytes, regulating blood pressure, and maintaining fluid balance. Performing this enormous workload requires an extraordinary amount of energy, making kidney cells some of the most mitochondria-rich cells in the human body.

But when those mitochondria begin to fail, the consequences can be severe.

When the Cell’s Power Plants Break Down

Healthy mitochondria constantly produce ATP—the molecule that powers nearly every cellular process.

Unfortunately, damaged mitochondria don’t simply make less energy.

They also begin producing excessive amounts of reactive oxygen species (ROS), unstable molecules that damage proteins, DNA, and cell membranes. Over time, this creates a vicious cycle of:

• Oxidative stress
• Chronic inflammation
• Cell death
• Tissue scarring (fibrosis)
• Progressive kidney dysfunction

Rather than being a consequence of kidney disease alone, mitochondrial dysfunction is increasingly viewed as one of its major driving forces. That’s why researchers are beginning to ask an important question:

What if we could protect the mitochondria before irreversible damage occurs?

Meet SS-31

SS-31—also known as elamipretide—is unlike traditional antioxidants.

Instead of circulating randomly throughout the body, this small synthetic peptide is engineered to travel directly into mitochondria, where it concentrates within the inner mitochondrial membrane.

There, SS-31 binds to cardiolipin, a specialized phospholipid that plays a critical role in maintaining mitochondrial structure and energy production.

The review notes that SS-31 can accumulate roughly 5,000-fold inside mitochondria, allowing it to act precisely where damage begins.

More Than an Antioxidant

Many compounds simply neutralize free radicals.

SS-31 appears to do considerably more.

According to the review, SS-31 may help:

•  Reduce mitochondrial oxidative stress
•  Preserve cardiolipin, a key component of the mitochondrial membrane
•  Prevent mitochondrial membrane breakdown
•  Restore ATP production
•  Prevent calcium overload
•  Reduce release of cytochrome c, a major trigger of programmed cell death
•  Improve the overall structure and function of damaged mitochondria

Rather than treating the downstream consequences of kidney disease, SS-31 targets one of the earliest points in the cascade: mitochondrial dysfunction itself. Figure 1 of the review illustrates how these effects may reduce oxidative stress, inflammation, fibrosis, and apoptosis while improving cellular energy production.

What Happens in Animal Studies?

One of the strengths of this review is the wide range of kidney disease models it examines.

Across studies, the findings are remarkably consistent.

Acute Kidney Injury

In models of ischemia-reperfusion injury—where blood flow is temporarily cut off and then restored—SS-31:

• Protected mitochondrial structure
• Accelerated ATP recovery
• Reduced tubular injury
• Lowered serum creatinine
• Reduced inflammation
• Reduced fibrosis

Even more impressive, some experiments found that treatment begun after kidney injury continued producing benefits months after therapy ended, suggesting that SS-31 may help restore damaged mitochondria rather than simply suppress oxidative stress temporarily.

Diabetic Kidney Disease

Diabetes places enormous stress on mitochondria.

Multiple studies reviewed showed that SS-31:

• Reduced protein leakage into urine
• Protected podocytes, the specialized cells responsible for filtration
• Reduced oxidative damage
• Improved mitochondrial dynamics
• Reduced inflammatory signaling
• Slowed structural kidney damage

Perhaps most interestingly, these improvements occurred without lowering blood glucose, suggesting the peptide was working directly on cellular energy systems instead of treating diabetes itself.

Additional Kidney Disorders

The review also summarizes encouraging findings in models of:

• Chronic kidney disease
• Contrast-induced kidney injury
• Drug-induced kidney injury
• Kidney injury caused by sepsis
• Obesity-associated kidney disease
• Renal artery stenosis
• Metabolic syndrome
• Unilateral ureteral obstruction

Although the diseases differed, the underlying pattern remained remarkably similar:

Healthier mitochondria were associated with healthier kidneys.

What About Human Studies?

This is where the science becomes more cautious.

The authors emphasize that human evidence remains limited.

The review highlights one randomized Phase IIa clinical trial involving 14 patients with severe renal artery stenosis undergoing angioplasty.

Patients receiving SS-31 experienced:

• Improved kidney blood flow
• Better kidney perfusion
• Improved estimated glomerular filtration rate (eGFR)
• Lower serum creatinine
• Good overall tolerability

These findings are encouraging, but the study was small. The authors conclude that much larger clinical trials are needed before SS-31 can be considered an established therapy.

Looking Beyond Oxidative Stress

One of the more intriguing sections of the review explores where future research may lead.

Because mitochondria regulate many forms of programmed cell death, the authors propose that SS-31 may eventually influence processes such as:

• Apoptosis (programmed cell death)
• Ferroptosis (iron-dependent oxidative cell death)
• Pyroptosis (inflammatory cell death)
• Necrosis (uncontrolled cell death)

These possibilities remain largely theoretical in kidney disease and require additional research, but they highlight how central mitochondria are to overall cellular health. Figure 2 presents these potential signaling pathways and future directions for investigation.

Is SS-31 Safe?

Based on the studies reviewed, SS-31 has demonstrated a favorable safety profile.

Reported side effects have generally been mild and include:

• Injection-site redness
• Itching
• Mild discomfort
• Headache
• Dizziness

No serious treatment-related adverse events were reported in the clinical studies discussed, though the review emphasizes that larger human trials are needed to fully characterize long-term safety.

Final Thoughts

Kidney disease has traditionally been treated by managing its consequences—controlling blood pressure, reducing blood sugar, or slowing disease progression.

SS-31 represents a different strategy.

Instead of focusing on the damage after it occurs, this mitochondria-targeting peptide aims to preserve the cellular machinery responsible for producing energy in the first place.

The preclinical evidence reviewed is compelling, with consistent improvements across multiple models of kidney disease. Early clinical findings are also encouraging, but the science is still developing.

For now, SS-31 should be viewed as a promising investigational therapy rather than a proven treatment. As larger human studies are completed, researchers hope to better understand whether protecting mitochondria can meaningfully change the course of kidney disease.

References

Zhu Y, Luo M, Bai X, et al. SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease. Oxidative Medicine and Cellular Longevity. 2022.

Read the full open-access article here:
https://pmc.ncbi.nlm.nih.gov/articles/PMC9192202

Learn about SS-31 here.